The first in vitro experiments with TNT003, a monoclonal antibody that is able to block the C1s component of the classical complement pathway, showed that its use inhibited complement activation in the samples of ITP patients, reducing Cd, C3b and C5b-9 deposits. This evidence concerns the gene CTLA4 and autoimmune thrombocytopenic purpura.